Herpes simplex vegetans in a patient with primary myelofibrosis.
Koushk-Jalali, Bijan; Oellig, Frank; Wieland, Ulrike; Kreuter, Alexander.
; 2019 Jun 04.
Artigo em Inglês | MEDLINE | ID: mdl-31165444
Distinguishing autoimmune myelofibrosis from primary myelofibrosis.
Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
Clinical and molecular genetic characterization of myelofibrosis.
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Prognostic risk models for transplant decision-making in myelofibrosis.
CALR mutation screening in pediatric primary myelofibrosis.
Advances in the management of myelofibrosis.
The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.